Loading clinical trials...
Loading clinical trials...
A PHASE 2, OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG TERM SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH MOTOR FLUCTUATIONS DUE TO PARKINSON'S DISEASE
Conditions
Interventions
1 mg QD to 15 mg QD PF-06649751
3 mg QD to 15 mg QD PF-06649751
+6 more
Locations
9
United States
Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States
Associated Neurologists of Southern CT, PC
Fairfield, Connecticut, United States
Parkinson's Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida, United States
Atlanta Center for Medical Research
Atlanta, Georgia, United States
Pharmaceutical Research Associates, Inc.
Marlton, New Jersey, United States
University of Toledo, Gardner-McMaster Parkinson Center
Toledo, Ohio, United States
Start Date
July 6, 2017
Primary Completion Date
October 24, 2017
Completion Date
October 25, 2017
Last Updated
April 12, 2019
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions